On November 10, Professor Rupert Josef Handgretinger, an internationally renowned pediatric oncology expert, member of the German Academy of Sciences, and former director of the Children's Hospital of Tübingen University, along with Professor Chen Zhifeng, former director of the Department of Hematology at Hong Kong Children's Hospital, honorary clinical professor of the Department of Child and Adolescent Sciences at the University of Hong Kong's Faculty of Clinical Medicine, and consultant physician at the University of Hong Kong, visited Shenzhen Cell Valley for an exchange. The visit was warmly received by Professor Shi Yuanyuan, Chairman of Cell Valley, Professor Wang Jianxun, Chief Scientist, Vice President Tang Xiaomeng, Dr. Fu Yuchen, Assistant to the Chairman, Dr. Feng Yaru, Director of Production, Dr. Zhang Xuefeng, Director of Quality Management, Dr. Zhao Lijun, Head of the R&D Department, and Dr. Zhu Wenxiang, Senior R&D Scientist. Both parties engaged in in-depth discussions on international collaboration in the field of cell and gene therapy, exploring the global application of cell therapy.
First, Chief Scientist Wang Jianxun and Chairman's Assistant Fu Yuchen accompanied Professor Handgretinger and Professor Chen Zhifeng on a tour of Cell Valley's smart exhibition hall, production workshop, R&D and quality control laboratories. They provided an initial introduction to Cell Valley's strategic layout in the field of cell and gene therapy, the founding team, and its unique advantages in core technologies such as reverse transcription viral vector preparation and cell product manufacturing processes. Both professors expressed high praise for Cell Valley's current development prospects and technological strengths.
Subsequently, at the exchange symposium, Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley, detailed the company's innovative achievements in the cell and gene therapy industry, its conversion platform, and future plans, emphasizing the strategic layout to promote the company's international development, always aiming for "technology research and development-clinical translation-global promotion." Professor Shi Yuanyuan stated that the domestic biomedical field is currently entering a golden period of development driven by both policy and demand. The "Regulations on the Clinical Research and Clinical Translation Application of New Biomedical Technologies" issued by the State Council of China provides clear regulatory guidance and institutional safeguards for industry development, while Cell Valley has established a one-stop service system of "research and development-production-clinical translation" through years of deep cultivation. Currently, Cell Valley has collaborated with over 100 tertiary hospitals and has obtained approval for more than 20 IIT clinical studies, as well as multiple international clinical trial registrations (NCT).
Professor Handgretinger highly commended Shenzhen Cell Valley's R&D and production capabilities in the field of cell therapy, particularly expressing admiration for its foundational technologies in viral vectors, industrialization capacity, and cost control in production. Leveraging his extensive experience in hematologic oncology treatment, Professor Handgretinger shared the latest advancements and clinical application cases in international cell and gene therapy technologies. He emphasized the undeniable importance of international academic exchange and collaboration in driving technological innovation and clinical applications in this field. He expressed anticipation for in-depth cooperation with Shenzhen Cell Valley in areas such as technical optimization and clinical translation, with plans to promptly deploy Cell Valley's products in hospitals across the Middle East and Southeast Asia. Professor Chen Zhifeng also stated that he would collaborate with Cell Valley to initiate clinical research and translation of cell therapy for pediatric hematologic malignancies in the Greater Bay Area as soon as possible.
The two parties will take this exchange as an opportunity to further expand the scope of cooperation, deepen the level of collaboration, and jointly promote the global development of cell and gene therapy technologies, contributing to the cause of human health.
take a group photo to mark the occasion
Prof. Rupert Handgretinger, MD PhD
Academician Leopoldina of the German National Academy of Sciences
Former Director of the University Children's Hospital Tübingen, Germany, Senior Professor, Emeritus Professor
Consultant, Abu Dhabi Stem Cell Center, UAE
George and Jennifer Yeo Chair Professor of Pediatric Oncology, Yang Luling School of Medicine, National University of Singapore
Professor Rupert Handgretinger pioneered novel pathways in tumor immunotherapy, represented by Bli natumomab, CAR-T, and graft-engineering, by closely integrating laboratory research with clinical treatment. His contributions to utilizing allogeneic transplantation techniques and developing safer immunotherapeutic interventions have advanced the global therapeutic strategies for high-risk pediatric leukemia.
Scan to follow our latest news Working hours: Monday to Friday, 9:00-18:00
Contact：Ms. Lai
Email：laijiaqi@chiuoho.com
Address：No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)
